The Burkitt Lymphoma drugs in development market research report provides comprehensive information on the therapeutics under development for Burkitt Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Burkitt Lymphoma. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Burkitt Lymphoma - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Burkitt Lymphoma and features dormant and discontinued products.

GlobalData tracks 70 drugs in development for Burkitt Lymphoma by 61 companies/universities/institutes. The top development phase for Burkitt Lymphoma is phase i with 22 drugs in that stage. The Burkitt Lymphoma pipeline has 56 drugs in development by companies and 14 by universities/ institutes. Some of the companies in the Burkitt Lymphoma pipeline products market are: Gilead Sciences, Wuhan Bio-Raid Biotechnology and Bristol-Myers Squibb.

The key targets in the Burkitt Lymphoma pipeline products market include Cells Expressing B Lymphocyte Antigen CD19 (B Lymphocyte Surface Antigen B4 or Differentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19), Cells Expressing B Lymphocyte Antigen CD20 (B Lymphocyte Surface Antigen B1 or Bp35 or Leukocyte Surface Antigen Leu 16 or Membrane Spanning 4 Domains Subfamily A Member 1 or CD20 or MS4A1), and B Lymphocyte Antigen CD19 (B Lymphocyte Surface Antigen B4 or Differentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19).

The key mechanisms of action in the Burkitt Lymphoma pipeline product include Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19 (B Lymphocyte Surface Antigen B4 or Differentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19) with 19 drugs in Phase III. The Burkitt Lymphoma pipeline products include six routes of administration with the top ROA being Intravenous and seven key molecule types in the Burkitt Lymphoma pipeline products market including Gene-Modified Cell Therapy, and Small Molecule.

Burkitt Lymphoma overview

Burkitt lymphoma is an aggressive and fast-growing type of non-Hodgkin lymphoma (NHL) that primarily affects B cells, a type of white blood cell involved in the immune system. It is named after Denis Burkitt, a surgeon who described the disease in African children in the 1950s. There are three main types of Burkitt lymphoma. Endemic Burkitt lymphoma is most commonly found in equatorial Africa, where it’s associated with the Epstein-Barr virus (EBV) infection and frequently affects children. It often presents as tumors in the jaw or facial bones. Sporadic Burkitt lymphoma is found worldwide, and is less associated with EBV but still affects children and adults. It can involve the abdomen, lymph nodes, bone marrow, or other organs. Immunodeficiency-associated Burkitt lymphoma occurs more commonly in individuals with weakened immune systems, such as those with HIV/AIDS or following organ transplantation. Burkitt lymphomas are characterized by rapid growth, often leading to the development of large tumors within a short period. Common symptoms include swelling of the lymph nodes, fever, night sweats, weight loss, and abdominal pain or swelling if organs in the abdomen are affected.

For a complete picture of Burkitt Lymphoma’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.